Abstract Library

#4059 Evaluation of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Systemic Immune–Inflammation Index (SII) as potential biomarkers in patients with sporadic pancreatic neuroendocrine tumors (pNET)

Introduction: Pancreatic neuroendocrine tumors (pNETs) are rare neoplasm in which the investigation of new biomarkers is essential. An elevated Neutrophile to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR) and Systemic Immune-Inflammation Index (SII) has been proposed as a negative prognostic factor in several neoplasms, but their role in pNET is unclear.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: pancreatic neuroendocrine tumor, neuroendocrine, cancer, biomarker, inflammation,

#4007 Inactivation of PHLDA3 gene leading to tumorigenesis of pancreatic neuroendocrine tumors and its molecular mechanisms

Introduction: The molecular mechanism underlying the tumorigenesis of sporadic pancreatic neuroendocrine tumors (PNETs) is largely unknown. Our previous studies showed that loss of heterozygosity (LOH) at chromosome 1q31 (including PHLDA3 gene) was frequently found in sporadic PNETs (2005 insulinoma and 2003 gastrinoma, respectively).

Conference:

Presenting Author: Song Y

Authors: Song Y, Tong W, Wang Z, Chen Y,

Keywords: pancreatic neuroendocrine tumor, PHLDA3, tumorigenesis, prognosis,

#3082 MEN1 Associated pNETs: A Case Series from Two Centres of Excellence in the United Kingdom

Introduction: Literature on MEN1 associated PNETS as a unique clinico-pathological entity is evolving.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Venkataraman H

Authors: Venkataraman H, Hegde P, Purewal T, Smith S, Vicarage S,

Keywords: Pancreatic neuroendocrine tumors, Multiple endocrine neoplasia, sporadic pancreatic neuroendocrine tumors,

#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,

Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,

#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?

Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Faggiano A,

Keywords: pancreatic neuroendocrine tumor, chemotherapy,